Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection-Reference-Cited by-同舟云学术

Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection

Published:2019-04-17 Issue:9 Volume:34 Page:1597-1603
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Wei Lai¹,Kumada Hiromitsu²,Perumalswami Ponni V³,Tanwandee Tawesak⁴,Cheng Wendy⁵,Heo Jeong⁶,Cheng Pin‐Nan⁷,Hwang Peggy⁸,Mu Sheng Mei⁹,Zhao Xu Min⁹,Asante‐Appiah Ernest⁸,Caro Luzelena⁸,Hanna George J⁸,Robertson Michael N⁸,Haber Barbara A⁸,Talwani Rohit⁸

Affiliation:

1. Peking University People's Hospital Beijing China

2. Toranomon Hospital Tokyo Japan

3. Icahn School of Medicine at Mount Sinai New York New York USA

4. Faculty of Medicine Siriraj Hospital Bangkok Thailand

5. Royal Perth Hospital Perth Western Australia Australia

6. College of Medicine, Pusan National University and Medical Research InstitutePusan National University Hospital Busan Korea

7. Department of Internal Medicine, National Cheng Kung University Hospital, College of MedicineNational Cheng Kung University Tainan Taiwan

8. Merck & Co., Inc. Kenilworth New Jersey USA

9. Merck, Sharp & Dohme Beijing China

Funder

Merck

Merck Sharp and Dohme

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.14636

Reference28 articles.

1. Global epidemiology and genotype distribution of the hepatitis C virus infection

2. MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

3. Discovery of MK-8742: An HCV NS5A Inhibitor with Broad Genotype Activity

4. A combination containing MK‐5172 (HCV N53 protease inhibitor) and MK‐8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in HCV replicons;Lahser F;Hepatology,2012

5. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress in diagnosis and treatment of hepatitis C;World Chinese Journal of Digestology;2024-07-28

2. Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open‐label, phase 2 study;Journal of Viral Hepatitis;2022-04-08

3. Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China;Frontiers in Pharmacology;2021-10-15

4. Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study;The Korean Journal of Internal Medicine;2021-03-01

5. Elbasvir and grazoprevir for the treatment of hepatitis C;Expert Review of Anti-infective Therapy;2021-01-17